Immunitybio reports third-quarter 2024 financial results

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx) today announced its financial results for the third-quarter ended september 30, 2024. anktiva® received a j-code (hcpcs level ii code) in october 2024, effective january 1, 2025. anktiva (fda-approved and commercially available in the u.s. since may 2024) is now widely accessible to patients through commercial and government insurance programs (va, dod, medicare). immunitybio has secured coverage for over 200 million medical.
IBRX Ratings Summary
IBRX Quant Ranking